Edwards Lifesciences Drops Merger With JenaValve
By Katherine Hamilton
Edwards Lifesciences said it no longer plans to acquire JenaValve after the Federal Trade Commission moved to block the deal.
A Washington, D.C., district court granted a motion from the FTC for an injunction blocking the proposed merger, the heart health company said Friday.
Edwards said it disagreed with the decision, saying the acquisition would have been in the best interest of patients.
The company also revised its full-year 2026 adjusted earnings guidance to a range of $2.90 to $3.05, down from $2.80 to $2.95.
The court's decision comes after the FTC in August filed a lawsuit to block the deal. The FTC said in its complaint that the acquisition would limit competition in the aortic regurgitation device market.
Edwards and JenaValve are the only two companies currently conducting clinical trials on transcatheter aortic valve replacement devices to treat aortic regurgitation in the U.S., according to the FTC.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 09, 2026 19:16 ET (00:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States